Our credit view of this issuer reflects its low leverage and improving credit metrics, constrained by its degree of event risk related to acquisitions.
The acquisition improves the company's respiratory pipeline in the context of patent cliffs arising later in the decade. Leverage metrics are unaffected
Our credit view of this issuer reflects its low leverage and improving credit metrics, constrained by its degree of event risk related to acquisitions.
Our credit view of this issuer reflects its diversified operations across pharmaceuticals and vaccines, against credit metrics which still require some improvement.